Here are worldwide third-quarter sales figures for some key Pfizer prescription drugs. Except for Enbrel and Prevnar, the decreases are due to generic competition.

PRODUCT NAME MAIN CONDITION/USE 3Q 2012 SALES 3Q 2011 SALES PERCENT CHANGE

Lipitor High cholesterol $749 million $2.6 billion down 71 percent

Lyrica Fibromyalgia/pain $1.04 billion $961 million up 8 percent

Enbrel (outside U.S.) Rheumatoid arthritis $893 million $957 million down 7 percent

Prevnar 13 Pneumococcal vaccine $868 million $1.01 billion down 14 percent

Celebrex Pain $676 million $643 million up 5 percent

Viagra Erectile dysfunction $517 million $493 million up 5 percent

Norvasc High blood pressure $319 million $350 million down 9 percent

Zyvox MRSA infections $328 million $321 million up 2 percent

Sutent Multiple cancers $294 million $298 million down 1 percent

Premarin/Prempro Menopause symptoms $262 million $267 million down 2 percent

___

Source: Pfizer Inc.




TOWNHALL MEDIA GROUP